Loading
Ovarian Function and Disorders · Journal article
Quality in Sport · August 8, 2026
A consensus or society position rather than new primary data.
This narrative review examines the bidirectional relationship between obesity and PCOS, emphasizing insulin resistance and hyperinsulinemia as key mediators. Emerging pharmacotherapies (GLP-1 agonists, alpha-lipoic acid, myo-inositol, D-chiro-inositol) show promise but the evidence base remains limited and heterogeneous; lifestyle modification is confirmed as the cornerstone of management.
Narrative review. Review literature on obesity, PCOS, and their management; no enrolled study population.
Obesity is identified as a major modifier of PCOS severity, exacerbating insulin resistance, metabolic dysfunction, infertility and psychological burden Emerging therapies including GLP-1 receptor agonists, alpha-lipoic acid, myo-inositol, and D-chiro-inositol show promising effects on metabolic and reproductive outcomes Current evidence for emerging therapies is limited and heterogeneous
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize obesity as a major exacerbating factor in PCOS severity and continue to prioritize lifestyle modification as first-line management. Emerging pharmacotherapies warrant further rigorous study before clinical implementation, but may offer future options.
A narrative review synthesizing pathophysiology, clinical consequences, and management strategies for obesity and PCOS, without presenting new primary data or a systematic appraisal of evidence quality.
As stated by the source record.
Clinicians should recognize obesity as a major exacerbating factor in PCOS severity and continue to prioritize lifestyle modification as first-line management. Emerging pharmacotherapies warrant further rigorous study before clinical implementation, but may offer future options.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background. Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in women of reproductive age and one of the leading causes of infertility. Insulin resistance plays a central role in its pathophysiology and leads to hyperinsulinemia, which is associated with an increased risk obesity in women with PCOS. Obesity in women with PCOS is associated with a more severe clinical phenotype, including increased risk of infertility, reduced response to ovulation induction, greater psychological burden, and impaired quality of life. First line management consists of lifestyle modification to reduce the risks of complications. The relationship between the multisystemic metabolic disorders, obesity and PCOS, is bidirectional and complex, with insulin resistance and hyperinsulinemia acting as key mediators linking the two conditions. Aim. This review critically examines the relationship between obesity and PCOS, focusing on underlying pathophysiological mechanisms, clinical consequences, and current and emerging management strategies. Material and methods. PubMed was used for the research of relevant studies with different combination of keywords; obesity and PCOS, management in obese PCOS women, complications in PCOS, therapeutic management in PCOS, therapeutic management in obese PCOS patients, PCOS and infertility, obesity and infertility and PCOS and lifestyle changes. Results. The available evidence indicates that obesity is a major modifier of PCOS severity, exacerbating insulin resistance, metabolic dysfunction, infertility and psychological burden. Emerging therapies, including GLP-1 receptor agonists, alpha-lipoic acid, myo-inositol, and D-chiro-inositol, show promising effects on metabolic and reproductive outcomes, although current evidence is limited and heterogeneous Conclusions. While emerging therapies demonstrate promising short-term benefits, lifestyle modification remains the cornerstone of management.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.